Avoro Capital Advisors LLC Reports New 5.75% Stake in Avalo Therapeutics, Inc.

Avoro Capital Advisors LLC and Dr. Behzad Aghazadeh have filed a Schedule 13G reporting a new 5.75% stake in Avalo Therapeutics, Inc. (AVTX). As of the event date of March 31, 2026, the reporting persons beneficially own 1,410,000 shares of common stock. Avoro Capital Advisors LLC, a Delaware limited liability company, serves as the investment advisor for Avoro Life Sciences Fund LLC, while Dr. Aghazadeh serves as the portfolio manager and controlling person. The filing indicates that the shares were acquired in the ordinary course of business for investment purposes and not with the intent to influence or change the control of the issuer. The ownership percentage is based on approximately 24.5 million shares outstanding as of late March 2026. This filing marks an increase from a previously reported 0% position, establishing the reporting persons as significant institutional holders in the pharmaceutical company.